A Genuine Breakthrough, and a Familiar Mistake
On 2 May 2026, The Lancet published a randomised controlled trial of semaglutide in people with alcohol use disorder and obesity. Over 26 weeks, participants receiving semaglutide alongside cognitive behavioural therapy reduced their heavy-drinking days by 41.1 percentage points from baseline, compared with 26.4 points in the placebo group. The difference between the groups was statistically significant. It was a small study, with 108 participants, but it adds to a growing body of evidence suggesting GLP-1 drugs may have a role in treating alcohol use disorder.
For a field in which medication options remain limited, anything that can reduce heavy drinking or craving deserves serious attention. It is also worth being precise about what the study showed. These participants had both alcohol use disorder and obesity, and they received cognitive behavioural therapy alongside the medication. Semaglutide is not yet a standalone answer to alcohol problems, and the evidence is still developing. Other trials have also found reductions in some drinking measures and craving, but not every outcome moves in the same direction.
I am not a clinician, and I have no view on who should take what. That belongs with a doctor. What interests me is the part that sits outside the trial: what happens when the craving becomes quieter and the rest of the life is still there.
The Craving Was Never the Whole Problem
It is easy to read a headline about Ozempic or Wegovy and imagine a straightforward sequence. Take the medication, lose the urge, problem solved. For some people the reduction in craving may be profound, and that is no small thing. But craving is only one part of why someone drinks.
Alcohol may have become the way they switch off after work, move through a room, tolerate loneliness, sleep, celebrate, avoid something, fill an evening, or make a difficult day feel briefly manageable. Sometimes those functions are obvious. Often they are not until the drinking starts to change.
If the chemical pull softens, the rest does not automatically disappear with it. The evening is still there. The anxiety may still be there. The relationships, routines and habits that grew around drinking are still there too. Sometimes what changes first is simply that there is now enough space to see them, and that space is where much of the work begins.
What Medication Cannot Do on Its Own
Addiction has never been well explained by biology alone. The biopsychosocial model remains useful precisely because it asks us to look at biology, psychology and social environment together. A GLP-1 drug may prove to be an important intervention on one part of that picture, but it does not by itself rebuild the parts of life that have narrowed around alcohol or drugs.
This is not an argument against medication. If craving is reduced, someone may have more room to think, more capacity to make different choices, and fewer hours of the day spent bargaining with themselves. That can be enormously valuable.
But recovery still has to happen somewhere. It happens at home, in relationships, in work, in the hours after everyone else has gone to bed, in the social situations that used to revolve around drinking, and in the first stretch of time when a person has to work out what they actually want their life to look like.
For some people, that is where sober companionship becomes useful. Not as an alternative to medical treatment, but alongside it, in the part of recovery that happens outside the consulting room.
The Work That Remains
If GLP-1 drugs continue to show benefit for alcohol use disorder, more people may arrive at the beginning of recovery with the volume turned down on one of its loudest features. That would be good news, and it may also make the rest easier to see.
What happens to the Tuesday night that used to disappear into drinking? What happens to the friendships built around it? What does someone do with the stress that alcohol used to interrupt, however briefly? What replaces the ritual, the reward, the escape? Those questions are slower, and more ordinary.
That is much of what I work with as a recovery coach: not deciding whether a medication is right, but helping someone work out what to do with the life that remains when the substance starts taking up less space. A quieter craving can be a remarkable beginning, but it is still a beginning.